35 related articles for article (PubMed ID: 1446882)
1. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries.
Satoh K; Yamada H; Taira N
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):76-82. PubMed ID: 1827660
[TBL] [Abstract][Full Text] [Related]
2. Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery.
Eltze M
Eur J Pharmacol; 1989 Jun; 165(2-3):231-9. PubMed ID: 2528466
[TBL] [Abstract][Full Text] [Related]
3. Specific antagonism by glibenclamide of negative inotropic effects of potassium channel openers in canine atrial muscle.
Satoh E; Yanagisawa T; Taira N
Jpn J Pharmacol; 1990 Oct; 54(2):133-41. PubMed ID: 2150209
[TBL] [Abstract][Full Text] [Related]
4. Vasodilatation of canine cerebral arteries by nicorandil, pinacidil and lemakalim.
Zhang H; Stockbridge N; Weir B; Vollrath B; Cook D
Gen Pharmacol; 1992 Mar; 23(2):197-201. PubMed ID: 1353469
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
Yanagisawa T; Teshigawara T; Taira N
Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290
[TBL] [Abstract][Full Text] [Related]
6. [The vasospasmolytic effects of nicorandil, cromakalim and pinacidil on 3,4-diaminopyridine-induced phasic contractions in canine coronary arteries as an experimental vasospasm model].
Kamijo T; Tomaru T; Miwa A; Nakamura F; Kido H; Sugimoto T; Uchida Y
Nihon Yakurigaku Zasshi; 1992 Oct; 100(4):317-27. PubMed ID: 1446882
[TBL] [Abstract][Full Text] [Related]
7. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
Satoh K
Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
[TBL] [Abstract][Full Text] [Related]
8. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential.
Longman SD; Hamilton TC
Med Res Rev; 1992 Mar; 12(2):73-148. PubMed ID: 1535674
[No Abstract] [Full Text] [Related]
9. Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
Atwal KS
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S12-7. PubMed ID: 7898103
[TBL] [Abstract][Full Text] [Related]
10. Cerebral vascular smooth muscle potassium channels and their possible role in the management of vasospasm.
Zhang H; Cook D
Pharmacol Toxicol; 1994 Dec; 75(6):327-36. PubMed ID: 7899253
[TBL] [Abstract][Full Text] [Related]
11. Smooth muscle K+ channel openers; their pharmacology and clinical potential.
Weston AH
Pflugers Arch; 1989; 414 Suppl 1():S99-105. PubMed ID: 2674897
[No Abstract] [Full Text] [Related]
12. [Advance in pharmacology of potassium channels in cardiovascular system and their clinical use].
Wu Y; Fang D
Zhonghua Yi Xue Za Zhi; 1992 Mar; 72(3):180-3. PubMed ID: 1319810
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
